A comparison of crizotinib treatment with chemotherapy in previously untreated patients and patients with progressive disease during previous chemotherapy demonstrated that crizotinib is more effective than chemotherapy in patients with ALK-rearranged NSCLC (10, 11). Here, ALK is linked to non-small cell lung carcinoma.